The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose...
Fiscal Calendar Year Changes from June to December Year End RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 16, 2023 Perspective, Therapeutics Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle...
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, WASHINGTON & CORALVILLE, IOWA – February...
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 6, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company...
Stockholders Approve Proposal One Clearing Way for Consummation of Merger RICHLAND, WASHINGTON – January 30, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, WASHINGTON – January 12, 2023 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual...
RICHLAND, WASHINGTON – December 14, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is...
Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WA and CORALVILLE, IA – October 18, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...
RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint)...
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 21, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
RICHLAND, WASHINGTON – June 21, 2022 – The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference...